uniQure Announces Sale of Royalty Interest in HEMGENIX for Up To $400 Million
uniQure N.V. announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure from CSL Behring from the net sales of HEMGENIX® (etranacogene…
Read More...
Read More...
